English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Milk is a common carrier for live cultures due to its abundant nutrients. Accumulating evidence has shown the efficacy of live culture as a vector to deliver drugs. This study aimed to develop recombinant  Lactococcus lactis  NZ9000-fermented milk expressing KRAS-139A-TTD mimotope. The fermentation conditions were optimized with inoculum concentration (6.4, 7, 8 log 10  CFU/mL), temperature (22–25, 30, 37°C), and time (3, 16, 24, 48 h). The optimized  L. lactis -fermented milk (8 log 10  CFU/mL inoculum, 48 h, and 30°C) had a viability of 9.79 log 10  CFU/mL, pH 5.16, and 0.54% titratable acidity. There was an absence of post-acidification and syneresis, with a 17.3% viability reduction after 26 days of storage at 4°C. Furthermore, the KRAS peptides expression in fermented milk after 10 days of storage was detected through SDS-PAGE. This showed that  L. lactis  NZ9000-fermented milk has the potential as KRAS positive therapeutic or prophylactic functional drink.

Development of therapeutic or prophylactic recombinant Lactococcus lactis NZ9000-fermented milk with KRAS mimotope